<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01228383</url>
  </required_header>
  <id_info>
    <org_study_id>RAB-M-A008</org_study_id>
    <secondary_id>U1111-1120-1647</secondary_id>
    <nct_id>NCT01228383</nct_id>
  </id_info>
  <brief_title>Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults</brief_title>
  <official_title>A Randomized, Single-blind, Active-controlled, Mono-center Phase II Study to Compare the Safety and Neutralizing Activity of Simulated Rabies Post-exposure Prophylaxis With CL184 in Combination With Purified Vero Cell Rabies Vaccine vs. Human Rabies Immune Globulin or Placebo in Combination With Purified Vero Cell Rabies Vaccine vs. CL184 or Placebo in Combination With Human Diploid Cell Rabies Vaccine in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Crucell Holland BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Crucell Holland BV</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study design:

      Single-blind (subject and observer-blinded), active-controlled, randomized [6:2:1:2:1; CL184
      + purified vero cell rabies vaccine (PVRV) vs. human rabies immune globulin (HRIG) + PVRV vs.
      placebo + PVRV vs. CL184 + human diploid cell vaccine (HDCV) vs. placebo + HDCV], mono-center
      study

      Study objectives:

      Primary: To evaluate the safety of CL184 in combination with PVRV in healthy adult subjects.

      Secondary: To evaluate the safety of HRIG or placebo in combination with PVRV and to evaluate
      the safety of CL184 or placebo in combination with HDCV in healthy adult subjects. To
      evaluate the rabies virus neutralizing activity (RVNA) after administration of CL184 or
      placebo in combination with PVRV, of HRIG in combination with PVRV, and of CL184 or placebo
      in combination with HDCV in healthy adult subjects. To evaluate the pharmacokinetics of the
      monoclonal antibodies (mAbs).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was designed to explore and obtain further safety and RVNA data on CL184 in
      comparison to HRIG and placebo as part of a classical post-exposure prophylaxis (PEP)
      regimen. This regimen will be applied as simulated PEP regimen to healthy subjects (i.e. in a
      pre-exposure setting) in this study. A comparison with placebo combined with each rabies
      vaccine was included to differentiate between the contribution of immune globulin and vaccine
      and to investigate potential interactions between immune globulin and vaccine. RVNA provided
      by CL184 or HRIG, as well as vaccination response will be checked regularly during the study
      and booster doses can be applied after the study, if necessary. In addition pharmacokinetic
      data will be collected.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of safety</measure>
    <time_frame>90 days</time_frame>
    <description>Assessed by recording unsolicited adverse events, solicited local and systemic adverse events, and pain at the injection site (assessed on a Visual Analog Scale from Day 0 to Day 3); routine safety laboratory assessed on Days -1, 1, 3, 7, 42, and 90; ECG and vital signs assessed on Days -1, 7, and 90.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rabies virus neutralizing activity</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Rabies</condition>
  <arm_group>
    <arm_group_label>CL184+PVRV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CL184 with rabies vaccine (PVRV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HRIG+PVRV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HRIG with rabies vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+PVRV</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo with rabies vaccine (PVRV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CL184+HDCV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CL184 with rabies vaccine (HDCV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+HDCV</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo with rabies vaccine (HDCV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rabies virus-specific monoclonal antibodies</intervention_name>
    <description>CL184 20 IU/kg intramuscularly on Day 0.</description>
    <arm_group_label>CL184+PVRV</arm_group_label>
    <arm_group_label>CL184+HDCV</arm_group_label>
    <other_name>CL184</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>human polyclonal rabies immune globulin (HRIG)</intervention_name>
    <description>HRIG 20 IU/kg intramuscularly on Day 0.</description>
    <arm_group_label>HRIG+PVRV</arm_group_label>
    <other_name>Imogam® Rabies-HT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo intramuscularly on Day 0.</description>
    <arm_group_label>Placebo+PVRV</arm_group_label>
    <arm_group_label>Placebo+HDCV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Human diploid cell vaccine (HDCV)</intervention_name>
    <description>Rabies vaccine (HDCV) given on Days 0, 3, 7, 14, and 28.</description>
    <arm_group_label>CL184+HDCV</arm_group_label>
    <arm_group_label>Placebo+HDCV</arm_group_label>
    <other_name>Imovax®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Purified verocell rabies vaccine (PVRV)</intervention_name>
    <description>Rabies vaccine (PVRV) given on Days 0, 3, 7, 14, and 28.</description>
    <arm_group_label>CL184+PVRV</arm_group_label>
    <arm_group_label>HRIG+PVRV</arm_group_label>
    <arm_group_label>Placebo+PVRV</arm_group_label>
    <other_name>Verorab™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subject aged ≥18 to ≤55 years

          -  Subjects free of obvious health-problems or with stable conditions or medications

          -  Body mass index between ≥18 to ≤30 kg/m2

          -  Abstinence from sexual intercourse or use of adequate contraception from the date of
             screening up to Day 90

          -  Male subjects must agree that they will not donate sperm from the first check-in until
             Day 90

          -  Subject signed written informed consent

        Exclusion Criteria:

          -  Prior history of active or passive rabies immunization

          -  Clinically significant acute illness or infection including fever (≥38 °C) within 2
             weeks before first dosing

          -  History and/or family history of clinically significant immunodeficiency or
             auto-immune disease

          -  Planned immunization with live vaccines during the coming 3 months after first dosing

          -  Chronic (longer than 14 days) administration of immunosuppressants or other
             immune-modifying drugs within 6 months before the first dose of investigational
             medicinal product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>G Nagashayana, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lotus Labs Pvt. Ltd, Bangalore, India</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lotus House, Vasanth Nagar</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560 052</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2010</study_first_submitted>
  <study_first_submitted_qc>October 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2010</study_first_posted>
  <disposition_first_submitted>March 20, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>March 20, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 28, 2013</disposition_first_posted>
  <last_update_submitted>April 3, 2013</last_update_submitted>
  <last_update_submitted_qc>April 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Monoclonal antibody</keyword>
  <keyword>Rabies</keyword>
  <keyword>Post-exposure prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rabies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

